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11 ABSTRACT: Protein−protein interactions drive every aspect
12 of cell signaling, yet only a few small-molecule inhibitors of
13 these interactions exist. Despite our ability to identify critical
14 residues known as hot spots, little is known about how to
15 effectively engage them to disrupt protein−protein inter-
16 actions. Here, we take advantage of the ease of preparation and
17 stability of pyrrolinone 1, a small-molecule inhibitor of the
18 tight interaction between the urokinase receptor (uPAR) and
19 its binding partner, the urokinase-type plasminogen activator
20 uPA, to synthesize more than 40 derivatives and explore their
21 effect on the protein−protein interaction. We report the
22 crystal structure of uPAR bound to previously discovered
23 pyrazole 3 and to pyrrolinone 12. While both 3 and 12 bind to uPAR and compete with a fluorescently labeled peptide probe,
24 only 12 and its derivatives inhibit the full uPAR·uPA interaction. Compounds 3 and 12 mimic and engage different hot-spot
25 residues on uPA and uPAR, respectively. Interestingly, 12 is involved in a π−cation interaction with Arg-53, which is not
26 considered a hot spot. Explicit-solvent molecular dynamics simulations reveal that 3 and 12 exhibit dramatically different
27 correlations of motion with residues on uPAR. Free energy calculations for the wild-type and mutant uPAR bound to uPA or 12
28 show that Arg-53 interacts with uPA or with 12 in a highly cooperative manner, thereby altering the contributions of hot spots to
29 uPAR binding. The direct engagement of peripheral residues not considered hot spots through π−cation or salt-bridge
30 interactions could provide new opportunities for enhanced small-molecule engagement of hot spots to disrupt challenging
31 protein−protein interactions.
32 I t is estimated that there are more than 200000 protein−33 protein interactions in a cell. These interactions drive nearly
34 every aspect of cellular function. Small molecules offer an
35 opportunity to explore these interactions in normal and
36 pathological processes. Protein−protein interactions exhibit a
37 wide range of binding thermodynamics and kinetics from weak
38 interactions that occur over small interfaces to tight and stable
39 protein−protein interactions that occur over large interfaces
40 (>1000 Å2). Although the design of small molecules to disrupt
41 weak interactions is relatively straightforward, inhibiting tight
42 interactions is much more challenging. To date, while
43 numerous small molecules have been reported to inhibit
44 protein−protein interactions (reviewed in refs 1 and 2), there
45 are only a few examples of small molecules that disrupt tight
46 protein−protein interactions (Kd = 1−100 nM); examples
47 include antagonists of Bcl-xL3 and IL-2R.4 The ability to disrupt
48 these tight interactions that occur over large surfaces with a
49 small molecule that has a much smaller footprint is attributed to
50the presence of residues that contribute disproportionately to
51the binding affinity, also known as hot spots.5−9
52The urokinase receptor (uPAR) is a cell surface glyco-
53phosphatidylinositol (GPI)-anchored receptor that is part of an
54extensive network of protein−protein interactions. Its binding
55partners include serine proteinase urokinase-type plasminogen
56activator uPA10 and the glycoprotein vitronectin.11−13 The
57uPAR·uPA protein−protein interaction is a high-affinity (KD =
581 nM) and stable (koff = 10
−4 s−1) interaction.14 Crystal
59structures of the uPAR·uPA complex show that uPA binds to
60uPAR along a well-defined binding site that is part of a >1000
61Å2 interface.15−18 The interaction is mediated by a 25-residue
62growth factor-like domain (GFD), and residues from a kringle-
63like domain of uPA. A comprehensive alanine scanning study at
Received: October 10, 2016
Revised: February 2, 2017
Published: February 10, 2017
Article
pubs.acs.org/biochemistry
© XXXX American Chemical Society A DOI: 10.1021/acs.biochem.6b01039
Biochemistry XXXX, XXX, XXX−XXX
sml00 | ACSJCA | JCA10.0.1465/W Unicode | research.3f (R3.6.i12 HF02:4458 | 2.0 alpha 39) 2016/10/28 09:46:00 | PROD-JCA1 | rq_7202739 | 2/15/2017 17:18:01 | 16 | JCA-DEFAULT
This is the author's manuscript of the article published in final edited form as:  Liu, D., Xu, D., Liu, M., Knabe, W. E., Yuan, C., Zhou, D., ... & Meroueh, S. O. (2017). Small Molecules 
Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein–Protein Interaction. Biochemistry, 56(12), 1768-1784. https://doi.org/10.1021/acs.biochem.6b01039
64 the uPAR·uPA interface identified several hot-spot residues that
65 reduced the uPAR·uPA binding affinity by >1 kcal mol−1.14,18,19
66 In the uPAR·uPA complex, there are hot spots both on uPA
67 (Trp-30, Phe-25, Tyr-24, and Ile-28)14 and on the large binding
68 cleft of uPAR that accommodates the GFD domain (Leu-150,
69 Leu-55, Leu-66, Tyr-57, and Asp-140).18
70 Previously, we performed a computational screen of
71 commercial libraries to identify small molecules that bind to
72 uPAR and disrupt the uPAR·uPA protein−protein interac-
73 tion.18,21,22 Compound 1 was discovered following a sub-
74 structure search using pyrazole, piperidinone, and pyrrolydi-
75 none compounds as templates.23 These compounds were
76 shown to bind to uPAR and displace a fluorescently labeled
77 peptide. In addition to 1, another strategy that consisted of
78 docking chemical libraries to an ensemble of uPAR structures
79 sampled from explicit-solvent molecular dynamics simulations
80 led to 2 (IPR-803).24 Compound 2 binds to uPAR with
81 submicromolar affinity and inhibits the uPAR·uPA complex
82 with single-digit micromolar IC50 values.
24 Structure−activity
83 relationships revealed the critical nature of a benzoic acid
84 moiety that was attributed to a salt-bridge interaction with the
85 guanidinium group of Arg-53. We showed that this residue
86 became exposed following explicit-solvent molecular dynamics
87 simulations.16 Our predicted binding mode and interaction
88 with Arg-53 was recently independently confirmed by a crystal
89 structure of an analogue of 2 bound to uPAR.25 To the best of
90 our knowledge, our work with 2 is the first study that led to
91 small-molecule protein−protein antagonists using protein
92 structures sampled from molecular dynamics simulations. The
93 work highlights the importance of considering molecular
94 dynamics of a receptor for the design of small molecules that
s1 95 disrupt tight interactions (Scheme 1).
96 Analysis of three-dimensional structures of protein−protein
97 complexes reveals that hot spots are generally found at the
98 protein−protein interface of tight protein−protein interac-
99 tions.5,26,27 They can be located either on the ligand or on the
100 receptor that harbors a binding site. It has been suggested that
101 small molecules that bind to hot spots can disrupt tight
102 protein−protein interactions despite their smaller footprint.
103 Early work targeting the IL-2·IL-2Rα complex confirmed that
104 small molecules that inhibited the interaction directly bind to
105hot spots,28 but the researchers also found that neighboring
106residues that promote IL-2·IL-2Rα enhanced binding of small
107molecules. These counterintuitive results can be explained by
108dynamical effects likely arising from the cooperativity of
109residues at the interface.29 This cooperativity has led to the
110suggestion that hot-spot clusters can form hot regions.30
111Cooperativity makes it more difficult to select the appropriate
112hot spots for the rational design of small-molecule inhibitors of
113protein−protein interactions. The mere binding to hot spots
114may not necessarily result in more potent inhibition of the
115protein−protein interaction. A deeper understanding of (i) the
116interaction energies between small molecules and individual
117residues and (ii) the dynamical changes that occur upon
118binding of a small molecule could lead to more effective
119strategies for the rational design of small-molecule protein−
120protein interaction inhibitors.
121Here, we take advantage of the straightforward synthesis of 1
122to prepare 46 derivatives of the compound to gain insight into
123the forces that lead to small-molecule inhibition of the uPAR·
124uPA protein−protein interaction. Their activity was measured
125using fluorescence polarization with a labeled α-helical peptide
126and an enzyme-linked immunosorbent assay (ELISA) that uses
127uPAATF, which includes the entire binding interface of the
128uPAR·uPA interface. We determine the crystal structure of
129uPAR bound to two small molecules, namely, pyrrolinone 21
130(IPR-1175) and pyrrazole 3 (IPR-737), providing a structural
131basis for the activity of 1 and its derivatives. To gain deeper
132insight into the basis for the activity of 1 and its derivatives, we
133conducted explicit-solvent molecular dynamics simulations of
134uPAR in complex with uPA, 1, 3, and several other derivatives.
135The resulting structures were used for free energy calculations
136using molecular mechanics (MM), generalized Born (GB), and
137solvent-accessible surface (SA) also known as MM-GBSA.
138Decomposition energy calculations, which correspond to the
139MM-GBSA free energy between a ligand and individual
140residues on uPAR, provided deeper insight into the individual
141contributions of each amino acid to the protein−protein and
142protein−compound interactions. Finally, we compare the
143dynamics of the uPAR·uPA interaction with the dynamics of
144uPAR in complex with small molecules.
145■ MATERIALS AND METHODS
146Protein Expression and Purification. suPAR was
147obtained by a one-step purification process as previously
148described.31
149Crystallization and Structure Determination of uPAR
150in Complex with Its Inhibitor, 3 (IPR-737), and 12 (IPR-
1511175). A stabilized form of human soluble uPAR (H47C/
152N259C) (denoted suPARcc) was used to facilitate crystal-
153lization of suPAR in complex with the inhibitor. suPARcc was
154expressed and purified as previously described32 and con-
155centrated to 16 mg mL−1. Crystals were formed using 1.96 M
156ammonium sulfate, 100 mM HEPES (pH 7.5), and 2% (w/v)
157polyethylene glycol 400 as the precipitant solution by the
158sitting-drop vapor diffusion method. Crystals were soaked into
15940% PEG4000 and 100 mM HEPES (pH 7.5) with 1 mM 3
160(IPR-737) or 12 (IPR-1175) for ∼2 days. X-ray diffraction data
161was collected under cryogenic conditions at 100 K. Crystals
162were collected on beamline BL17U at the Shanghai
163Synchrotron Radiation Facility (SSRF) and were processed,
164integrated, and scaled together with HKL2000.33 The crystal
165structures of the suPARcc·3 (IPR-737) complex and suPARcc·
16612 (IPR-1175) complex were determined by the molecular
Scheme 1
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167 replacement program MOLREP34 of the CCP4 package using
168 Protein Data Bank (PDB) entry 3U74 as a search model. After
169 molecular replacement, inhibitor 3 (IPR-737) or 12 (IPR-
170 1175) was built into the model on the basis of a 2Fobs − Fcalc σ-
171 weighted composite omit map, and then iterative manual model
172 building and model refinement were performed with COOT35
173 and REFMAC, yielding a final R value of 0.2119 and an Rfree
174 value of 0.2576 in the suPARcc·3 (IPR-737) complex (Table
175 S2), while the values were 0.2349 and 0.2613, respectively, in
176 the suPARcc·12 (IPR-1175) complex (Table S1). These
177 structures were analyzed by PyMOL.4
178 Fluorescence Polarization. Polarized fluorescence inten-
179 sities were measured using an EnVision Multilabel plate reader
180 (PerkinElmer) with excitation and emission wavelengths of 485
181 and 530 nm, respectively.24 A Thermo Scientific Nunc 384-well
182black microplate was used to prepare samples with a final
183volume of 50 μL in duplicate. First, the compounds were
184serially diluted in dimethyl sulfoxide (DMSO) and further
185diluted in 1× PBS buffer with 0.01% Triton X-100 to yield a
186final concentration from 100 to 0.046 μM. Triton X-100 was
187added in the buffer to avoid compound aggregation; 35 μL of
188the compound solution and 10 μL of PBS containing uPAR
189were added to the wells, and the mixture was incubated for at
190least 15 min to allow the compound to bind to the protein.
191Finally, 5 μL of fluorescent AE147-FAM peptide was added for
192a total volume of 50 μL in each well, resulting in final uPAR and
193peptide concentrations of 320 and 100 nM, respectively. The
194final DMSO concentration was 2%, which had no effect on the
195binding of the peptide. Controls included wells containing only
196the peptide and wells containing both protein and peptide each
Table 1. continued
aMolecular weight. bHydrogen bond acceptor. cHydrogen bond donor. dRotatable bonds.
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197 in quadruplicate to ensure the validity of the reaction assay. A
198 unit of millipolarization (mP) was used to calculate the percent
199 inhibition of the compounds. Inhibition constants were
200 determined using the Ki calculator available at http://sw16.
201 im.med.umich.edu/software/calc_ki/.
202 Microtiter-Based ELISA for uPAR·uPA. High-binding
203 microplates (Greiner Bio-One) were incubated for 2 h at 4 °C
204 with 100 μL of 2 μg mL−1 uPAATF in PBS. Each plate was
205 washed with 0.05% Tween 20 in PBS buffer between each step.
206 A 1:1 mixture of Superblock buffer in PBS (Thermo Fisher
207 Scientific, Inc., Waltham, MA) with 0.04 M NaH2PO4 and 0.3
208 M NaCl buffer was used for blocking at room temperature for 1
209 h; 100 μL of 75 nM uPAR in PBS with 0.025% Triton X-100
210 was added with the indicated concentrations of compounds.
211 Compounds were screened initially at 50 μM. For concen-
212 tration-dependent studies, a range of compound concentrations
213 from 100 to 0.4 μM were used. The final DMSO concentration
214 was 1%. Following incubation for 30 min and subsequent
215 washing steps, the human uPAR biotinylated antibody (1:3000
216 dilution of 0.2 mg mL−1 BAF807, R&D Systems, Minneapolis,
217 MN) in PBS containing 1% BSA was added to the wells (100
218 μL/well) and incubated for 1 h to allow for the detection of
219 bound uPAR. Following washing, 100 μL of streptavidin-bound
220 horseradish peroxidase (84 ng mL−1) in PBS containing 1%
221 BSA was added for 20 min. The signal obtained in the presence
222 of TMB in phosphate-citrate buffer (pH 5) and hydrogen
223 peroxide was stopped by adding a H2SO4 solution and detected
224 using a SpectraMax M5e instrument (Molecular Devices,
225 Sunnyvale, CA).
226 Molecular Docking. Small molecules were prepared for
227 molecular docking using Maestro (version 9.4, Schrödinger,
228 LLC, New York, NY). Compounds were first processed with
229 LigPrep (version 2.6, Schrödinger, LLC). The receptor protein
230 structure (PDB entry 3BT1 and crystal structures of the uPAR·
231 3 and uPAR·12 complexes) was prepared using the Protein
232 Preparation Wizard workflow in Maestro. Bond orders were
233 assigned, hydrogen atoms added, and disulfide bonds created.
234 For the 3BT1 structure, vitronectin (chain B) was removed and
235 the missing loop at residues Arg-83 and Ala-84 introduced
236 using the Prime36 module in Schrödinger. The missing loops
237 from Ser-81 to Ser-90 (uPAR·3) and from Ile-129 to Lys-139
238 (uPAR·3 and uPAR·12) were reconstructed using the loop-
239 model class in MODELER (version 9.13).37 Five initial models
240 were constructed and refined using the “fast” molecular
241 dynamics (MD) annealing function. Five additional loop
242 models were constructed for each initial model and similarly
243 refined. A loop model was visually selected from the 25 loop
244 models that best matched the existing loop in the 3BT1
245 structure. Finally, structures were protonated at pH 7.0 using
246 PROPKA.38
247 The binding poses of select derivatives of 1 (IPR-1110) were
248 generated using the cocrystal structure of uPAR in complex
249 with 3 (IPR-1175) as a guide in Maestro. The derivatives were
250 docked in a 21 Å box centered on the complexed ligand using
251 Glide39 (Schrödinger, LLC) in standard precision (SP) mode.
t1 252 The common core structure of the analogues found in Table 1
253 was used to restrict the binding poses of the derivative
254 compounds. All other parameters were set to default values.
255 Molecular Dynamics Simulations. The binding poses
256 were used to run MD simulations using the AMBER14 and
257 AmberTools15 packages.40 Each compound was assigned AM1-
258 BCC41 charges and gaff42 atom types using the antechamber
259 program.43 Complexes were immersed in a box of TIP3P44
260water molecules. No atom on the complex was within 14 Å of
261any side of the box. The solvated box was further neutralized
262with Na+ or Cl− counterions using the tleap program.
263Simulations were performed using the GPU accelerated
264version of the pmemd program with ff12SB45 and gaff42 force
265fields under periodic boundary conditions. All bonds involving
266hydrogen atoms were constrained by using the SHAKE
267algorithm,46 and a 2 fs time step was used in the simulation.
268The particle mesh Ewald47 (PME) method was used to treat
269long-range electrostatics. Simulations were run at 298 K under
2701 atm in the NPT ensemble employing a Langevin thermostat
271and a Berendsen barostat. Water molecules were first energy-
272minimized and equilibrated by running a short simulation with
273the complex fixed using Cartesian restraints. This was followed
274by a series of energy minimizations in which the Cartesian
275restraints were gradually relaxed from 500 to 0 kcal Å−2, and the
276system was subsequently gradually heated to 298 K via a 48 ps
277MD run. Via assignment of different initial velocities, 10
278independent simulations that are 10 ns in length each were
279performed for the protein−compound structures.
280Free Energy Calculations. In each of the 10 trajectories
281(10 ns in length), the first 2 ns was discarded for equilibration.
282MD snapshots were saved every 1 ps, yielding 8000 structures
283per trajectory. A total of 80000 snapshots were generated per
284100 ns of simulation; 1000 snapshots were selected at regular
285intervals from the 80000 snapshots for free energy calculations
286using the cpptraj program.48 The molecular mechanics-
287generalized Born surface area (MM-GBSA)49 method was
288used to calculate the free energy using the MMPBSA.py script50
289and Onufriev’s GB model.51,52 Solvent-accessible surface area
290(SASA) calculations were switched to the ICOSA method,
291where surface areas are computed by recursively approximating
292a sphere around an atom, starting from an icosahedron. Salt
293concentrations were set to 0.1 M. The entropy was determined
294by normal mode calculations53 with the nmode module from
295100 of the 1000 snapshots used in the free energy calculations.
296The maximal number of cycles of minimization was set to
29710000. The convergence criterion for the energy gradient to
298stop minimization was 0.5.
299The MM-GBSA binding free energy is expressed as
Δ = Δ − Δ‐G E T SMM GBSA GBTOT NM
300where ΔEGBTOT is the combined internal and solvation
301energies, T is the temperature, and ΔSNM is the entropy
302determined by normal mode calculation. The solvation energy
303is determined using generalized Born (GB) solvation models
304(ΔEGBSOL) (igb = 2):
Δ = Δ + ΔE E EGBTOT GBSOLV GAS
305where ΔEGBSOLV is the solvation free energy and ΔEGAS is the
306molecular mechanical energies (gas phase). The gas-phase
307energies are composed of two components:
Δ = Δ + ΔE E EGAS ELE VDW
308where ΔEELE is the nonpolar electrostatic energy and ΔEVDW is
309the polar van der Waals energy. The GB solvation free energy is
310expressed by
Δ = Δ + ΔE E EGBSOLV SURF GB
311where ΔESURF and ΔEGB are the nonpolar and polar
312contributions to the solvation free energy, respectively. All
313the binding energies are determined by
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Δ = − −E E E ECOM REC LIG
314 where ECOM, EREC, and ELIG are total energies corresponding to
315 the complex, receptor, and ligand, respectively.
316 Decomposition Energy. The decomposition energy used
317 in this work was determined using the MMPBSA.py script50
318 available in AMBER14. The script provides several schemes for
319 decomposing calculated free energies into specific residue
320 contributions using either GB or PB implicit-solvent models.
321 These schemes were developed by Gohlke and co-workers.54
322 The per-residue decomposition scheme was used in this work.
323 Similar to the free energy calculations, we use the GB solvation
324 model from Onufriev and co-workers.51,52 The energy terms
325 are decomposed according to the scheme outlined in the
326 AMBER14 manual using the following equation:
∑
∑
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327 where the first and second terms represent the average
328 contribution over snapshots i from the MD simulation in
329 residues j on the receptor and ligand, respectively. The term
330 E(i,j) corresponds to the contribution of the gas-phase and
331 solvation energies, that is
= +
= + + +
E i j E i j E i j
E i j E i j E i j E i j
( , ) ( , ) ( , )
( , ) ( , ) ( , ) ( , )
GAS GBSOLV
VDW ELE GB SURF
332 where EVDW and EELE are the van der Waals and electrostatic
333 energies in the gas phase (EGAS), respectively. EGB and ESURF are
334 the polar and nonpolar contributions to the solvation free
335 energy by the GB solvation model (EGBSOLV), respectively.
336 Entropy is not included in the decomposition method.
337 The GB model is described in detail by Onufriev and
338 associates55 and in the AMBER14 manual. The GB model we
339 selected (igb = 2, GBOBC model I) approximates the solvation
340 electrostatic EGB by an analytical formula:
∑ ε= − −
−Κ⎡
⎣⎢
⎤
⎦⎥E
q q
f
f1
2
1
exp( )
ij
i j
GB GB
GB
341 where rij is the distance between atoms i and j, Ri and Rj are the
342 effective Born radii of atoms i and j, respectively, K is the
343 Debye−Hückel screening parameter, ε is the dielectric
344 constant, and f GB is a smooth function. Each atom in the GB
345 model is represented as a sphere with radius ρi with charge qi.
346 The f GB function is expressed as
= + −
⎛
⎝
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⎞
⎠
⎟⎟f r R R
r
R R
exp
4ij i j
ij
i j
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2
347 and is used to describe the distance between two atoms and
348 their effective Born radii.
349 The nonpolar contribution to the solvation free energy is
350 calculated by approximating the total SASA of the molecule:
γ β= +E SASASURF
351where γ and β are the surface tension and offset terms,
352respectively. The ICOSA method is used to determine
353SASA.40,54 In this method, surface areas are computed by
354recursively approximating a sphere around an atom. The first
355sphere is modeled as an icosahedron. In each subsequent step,
356the faces of the polyhedron are divided into four equal-sized
357triangles to better approximate the sphere.
358Chemistry. All chemicals were purchased from commer-
359cially available sources and used as received. Column
360chromatography was performed with silica gel (25−63 μm).
361High-resolution mass spectra were recorded on an Agilent 6520
362Accurate Mass Q-TOF instrument. 1H nuclear magnetic
363resonance was recorded in CDCl3 or DMSO on a Bruker
364500 MHz spectrometer. Reverse-phase liquid chromatography
365and mass spectrometry were performed on an Agilent 1100
366LC/MSD instrument fitted with an Eclipse XBD-C18 (4.6 mm
367× 150 mm) column eluting at 1.0 mL min−1 employing an
368(acetonitrile/methanol)/water gradient (each containing 5 mM
369NH4OAc) from 70 to 100% acetonitrile/methanol over 15 min
370and holding at 100% acetonitrile/methanol for 2 min. Chemical
371shifts are reported in parts per million using either residual
372CHCl3 or DMSO as an internal reference. All compounds are
373>95% pure unless otherwise stated. Syntheses of 3-(hexyloxy)-
374aniline and 3-(hexyloxy)-4-methylaniline were performed using
375a protocol described by Marco and co-workers.56 β-
376Diketoesters were synthesized with modification according to
377Milagre and co-workers.57 Derivatives of 1 were synthesized by
378a modified procedure of Rose and co-workers.58 Full
379compound characterization is provided in the Supporting
380Information.
381■ RESULTS
382Synthesis of Pyrrolinones, Stability, Reactivity, and
383Selectivity Studies. The ease of synthesis of 1 (IPR-1110)
384prompted us to prepare 46 derivatives to explore the uPAR·
385uPA binding interface (Table 1). 1 (IPR-1110) was modified at
386three sites, R1−R3. Most of the structure−activity exploration
387was focused on R1 and R2. The synthesis of these compounds
388was straightforward (Figure S1) as described previously.23
389The pyrrolinone core structure of 1 suggests that
390nucleophilic residues within a protein could potentially form
391covalent adducts through nucleophilic attack at the carbon
392bearing the hydroxyl group of the core five-membered ring. To
393explore this possibility, we employed electrospray ionization
394(ESI) mass spectrometry. As shown in Figure S2, there was no
395adduct formation when uPAR was incubated with the
396compound, ruling out nonspecific covalent bond formation as
397the mechanism by which the pyrrolinone compounds
398antagonize uPAR−protein interactions. Next, we investigated
399the stability of the compound in buffer (PBS), methanol, and
400uPAR using high-performance liquid chromatography (Figure
401S3). The UV spectra for all three conditions were identical
402(Figure S3a), and the mass spectra corresponding to the major
403peaks were also identical (Figure S3b). This suggests that the
404compound is stable both in buffer and in the presence of uPAR.
405Finally, we investigated the selectivity of the pyrrolinone
406compounds by testing them for inhibition of an unrelated
407protein−protein interaction between the α and β subunits of
408the CaV2.2 calcium channel (Figure S4). The CaVαβ
409interaction is mediated by a tight single-digit nanomolar
410interaction that occurs over a large interface consisting
411primarily of an α helix of the α subunit binding to a large
412well-defined pocket on the β subunit (Figure S4). Compound 1
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413 (Figure S4) showed no inhibition of this interaction up to 25
414 μM. The effect of 1 on the CaVαβ interaction at 50 and 100
415 μM can be attributed to aggregation considering the sharp rise
416 in activity from nearly 0% inhibition at 25 μM to more than
417 75% inhibition at 50 μM. This was not observed for uPAR,
418 whereby 1 exhibited a gradual increase in its level of inhibition
419 of binding of AE-147 to uPAR (Figure S4). These studies
420 confirm that the compounds bind to uPAR in a selective
421 manner as evidenced by the lack of activity against another
422 unrelated protein−protein interaction. It is possible that
423 compound 1 inhibits interactions that are similar to the
424 uPAR·uPA interaction. Future studies that explore compounds
425 in cell culture should explore these compounds for inhibition of
426 interactions that are similar to uPAR·uPA interactions.
427 Crystal Structures of Compounds Bound to uPAR. The
428 crystal structure of uPAR was previously determined in
f1 429 complex with ATF (PDB entry 2FD6) (Figure 1a) or α-helical
430 peptide AE-147 (PDB entry 1YWH) (Figure 1b). These
431 structures revealed a large interface between uPAR and uPA
432 that contains several hot spots, including Leu-55, Tyr-57, Leu-
433 66, Asp-140, and Leu-150. All the hot spots on uPAR at the
434 uPAR·uPA interaction are listed in Table S1. We hypothesized
435 that compounds that disrupt the protein−protein interaction
436 between uPAR and uPA likely directly engage these hot spots.
437 To test this hypothesis, we resorted to X-ray crystallography to
438 determine the structure of 1 (IPR-1110) and derivatives in
439 complex with uPAR. We also attempted to determine the
440 structures of pyrazole, piperidinone, pyrrolidinone, and butan-
441 amine compounds that we had previously shown to bind to
442 uPAR.21 We obtained structures for two compounds bound to
f2 443 uPAR, namely, pyrrolinone 12 (IPR-1175) (Figure 2 and Table
f3 444 S2) and pyrazole 3 (IPR-737) (Figure 3 and Table S3).
445 The structure of uPAR in complex with 12 reveals that the
446 compound is ensconced deeply in the pocket that is occupied
447by the growth factor-like domain of uPA in its complex with
448uPAR (Figure 2a). The R1 isopropylphenyl group of the
449compound points toward the interior of the hydrophobic
450pocket of uPAR. This pocket accommodates the residues
451located on the loop of the β turn of the GFD domain of uPA.
452The substituent makes direct contacts with Leu-150, Leu-168,
453Val-125, Leu-55, and Arg-53 (Figure 2b). Most of these
454interactions are hydrophobic except for the cation−π
455interaction with Arg-53. Cation−π interactions are commonly
456observed in protein−compound structures and can contribute
457up to 1 kcal mol−1 to the free energy of binding.59,60 Here, the
458benzene ring of the R1 group of 12 (IPR-1175) directly faces
459one of the Nω atoms of the guanidinium ion of Arg-53. The
460Nω atom is 2.5 Å from one of the ortho carbon atoms of the
461benzene ring. Unlike R1, the chlorobenzene R3 group of 12
462(IPR-1175) points in the opposite direction and occupies a
463pocket surrounded by residues Thr-27, Val-29, Arg-142, and
464Leu-40 on uPAR. The R3 group is more exposed to solvent
465than R1 and does not occupy a pocket composed entirely of
466hydrophobic residues as evidenced by the presence of Arg-142.
467Finally, the R2 group of 12 does not occupy a well-defined
468pocket on uPAR, but it is worth noting that this group is also
469involved in a cation−π interaction with Arg-53 of uPAR (Figure
4702b). Interestingly, the R1 and R3 groups of 12 occupy the same
471position as uPA hot spots Ile-28 and Tyr-24, respectively
472(Figure 2c).
4733 (IPR-737) adopts a binding mode different from that of 12
474(IPR-1175) (Figure 3). 3 (IPR-737) binds outside the
475hydrophobic pocket of uPAR that is occupied by side chains
476of the β-turn loop of the GFD domain of uPA (Figure 3a).
477Unlike 12 (IPR-1175), the compound engages fewer hot spots
478on uPAR (Figure 3b). Only one of the uPAR hot-spot residues
479(Leu-66) comes in contact with 3 (IPR-737). Interestingly,
480analysis of the crystal structure of uPAR in complex with the
Figure 1. (a) Three-dimensional structure of the uPAR·uPAATF complex (PDB entry 2FD6). uPAR is shown as a gray solvent-accessible surface.
Residues whose mutations to alanine result in changes in binding affinity of ≥1 kcal mol−1 are colored red, while those that lead to changes between
0.5 and 1 kcal mol−1 are colored purple. uPAATF is shown as an orange cartoon. (b) Three-dimensional structure of uPAR in complex with the AE-
157 peptide (PDB entry 1YWH). The peptide is shown as a cyan cartoon, and side chains that come in contact with uPAR are shown as capped
sticks. uPAR is rendered and color-coded in a manner similar to that of panel a.
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481 AE-147 peptide shows that two hydrophobic residues on the
482 peptide (Phe-5 and Tyr-8) come in direct contact with Ile-66 of
483 uPAR (Figure 1b). Hence, interaction with Ile-66 may explain
484 why 3 (IPR-737) can disrupt binding of AE-147 to uPAR.
485 Engagement of Ile-66, however, is not sufficient to disrupt the
486 full uPAR·uPAATF interaction. Ile-66 of 3 (IPR-737) binds to
487 uPAR at a site that is occupied by Ile-28 and Trp-30 of uPA.
488 These two residues are located on the β strands of the β hairpin
489 of the GFD domain of uPA (Figure 3c). This is in contrast to
490 12 (IPR-1175), which overlaps with amino acids located on the
491 loop region of the β hairpin (Figure 2c).
492 Structure−Activity Relationship. We prepared 46
493 derivatives of 1 (IPR-1110) to explore the uPAR binding site
494 at the uPAR·uPA interface. Substituents at R1−R3 of 1 (IPR-
495 1110) were explored. The binding mode of 12 (IPR-1175)
496 (Figure 2a,b) shows that R1 groups point toward a large
497 hydrophobic cavity occupied by several uPA hot-spot residues.
498 An aromatic group at R1 was generally required for inhibition of
499 uPAR·uPA interaction. This is evidenced by complete loss of
500 activity of 25 (IPR-1177), which lacks an aromatic ring at R1.
501 There are six compounds without an aromatic ring directly
502 attached to the central pyrrolidone ring: 26, 32, 34, 38, 39, and
503 46; in these compounds, a methylene (34) or an ethylene (26,
504 32, 38, 39, and 46) group separates the central pyrrolinone ring
505 with a benzene ring. Except for 26, 34, and 38, the compounds
506 retained the ability to inhibit the uPAR·uPA protein−protein
507 interaction with IC50 values similar to that of 1 (IPR-1110) for
508 39 and 46. All three compounds that did not inhibit uPAR·uPA
509interaction have fluorine atoms on the aromatic ring at R1,
510suggesting that highly polar groups may not be suitable for the
511binding site on uPAR. Interestingly, the compounds bind to
512uPAR with a Ki of 1−2 μM. Replacing the bromine atom at R1
513with an iodine such as in 13 (IPR-1171) had no effect on the
514IC50 but gave a 2-fold reduction in binding affinity. Removal of
515the bromine group at the meta position and replacing the
516methyl group with an isopropoxy group in 12 (IPR-1175) or a
517tert-butyl group such as in 15 (IPR-1195) led to a 2−3-fold
518increase in the IC50 and a nearly 2-fold increase in Ki. A
519benzyloxy group in 16 (IPR-1186) increased the IC50 and Ki by
5203-fold versus those of 1 (IPR-1110). Generally, replacing the
521hydrogen atoms at the meta position of the aromatic ring
522directly attached to the central pyrrolidone ring reduced activity
523substantially as evidenced by a 5-fold increase in IC50 and a 20-
524fold increase in Ki for 37. Larger groups at one of the meta
525positions were also generally undesirable as most compounds
526had pronounced increases in IC50 such as 36 and 41. For these
527compounds, it is interesting that 36 retained almost all of its
528binding affinity as evidenced by a Ki of 1.9 μM that was 2-fold
529higher than that of 1 (IPR-1110). Compound 41 had reduced
530affinity, but its Ki value was within 10 μM. Introduction of
531various substituents at the para position generally weakened the
532ability to disrupt the uPAR·uPA protein−protein interaction
533(e.g., 19 and 36), except for 44 (IPR-1607) and 45 (IPR-2260).
534Both of these compounds had IC50 values similar to that of 1
535(IPR-1110). Interestingly, the compound showed a nearly 2-
Figure 2. Mode of binding of 12 (IPR-1175) upon the central ligand binding cavity of suPARcc. suPARcc is shown as a gray solvent-accessible
surface. 12 (IPR-1175) is shown as capped sticks. Atoms are color-coded by atom type with N, C, O, Cl, and F colored blue, yellow, red, green, and
light blue, respectively. The 2Fo − Fc electron density map of 12 (IPR-1175) at 1σ is colored blue. (b) Crystal structure of 12 (IPR-1175) bound to
uPAR except that uPAR is shown as capped sticks to highly hot-spot residues located within the uPAR cavity. Hot spots are shown as red capped
sticks. Arg-53, which is not considered a hot spot, is colored green. (c) Crystal structure of the uPAR·12 (IPR-1175) complex superimposed on the
structure of the uPAR·uPAATF complex to illustrate the overlap between hot spots on uPA and substituents on 12 (IPR-1175).
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536 fold increase in its binding affinity for uPAR as evidenced by a
537 Ki of 0.4 μM compared with a Ki of 0.9 μM for 1 (IPR-1110).
538 Despite the highly favorable cation−π interaction of the R2
539 group with Arg-53, the substituent has significant exposure to
540 solvent. The addition of a methoxy group at the meta position
541 of the aromatic ring of R2 (21 and 28) reduced the binding
542 affinity and weakened the potency for inhibition of uPAR·uPA
543 interaction. Replacing the fluorine on 4 (IPR-1201) with a
544 chlorine on 7 (IPR-1178), however, does not have much
545 impact on the binding affinity or inhibition of uPAR·uPA.
546 Moving the fluorine from the meta to ortho position on 10
547 reduces the Ki and IC50 by 2-fold. It is interesting to note that a
548 methoxy group at the meta position of 21 has a much more
549 significant impact on both binding with a 10-fold reduction in
550 Ki and inhibition of the protein−protein interaction as
551 evidenced by a nearly 5-fold increase in IC50. Replacing the
552 hydrogen atom with a fluorine atom of this compound to
553 generate 28 improves the Ki and IC50 by 5-fold versus those of
554 compound 21. In compound 24, we introduced a tert-butyl
555 group at the para position of the aromatic ring at R2, which led
556 to complete abrogation of the inhibition of uPAR·uPA
557 interaction (IC50 not determined), although direct binding to
558 uPAR was still detected but its level was reduced by more than
559 an order of magnitude (Ki = 15.9 ± 2.8 μM). A nearly similar
560 effect was observed for 33 (IPR-1157), and an even more
561dramatic effect when a methoxy group was introduced at the
562para position of R2 with no inhibition or binding detected
563within the 100 μM range.
564Molecular Dynamics Simulations and Free Energy
565Calculations. To further explore the interaction between
566compounds and individual amino acids at the uPAR·uPA
567interface, we resorted to explicit-solvent molecular dynamics
568simulations and free energy calculations. We also performed
569free energy decomposition calculations to investigate the
570interaction of each amino acid with the compounds. First, we
571generated a model for the structure of 12 derivatives of 1 (IPR-
5721110) bound to uPAR using the binding mode of 12 (IPR-
5731175). These compounds were selected to ensure a uniform
574distribution across the range of binding affinities. Along with 3
575(IPR-737) and 12 (IPR-1175), these complexes were subjected
576to 100 ns explicit-solvent molecular dynamics simulations.
577Snapshots were collected at regular intervals, and free energy
578calculations using the MM-GBSA approach were conducted for
579 f4each of the compounds as shown in Figure 4a and Table S4. It
580is worth noting that end-point free energy calculations cannot
581accurately reproduce the absolute value of the free energy of
582binding. These calculations, however, have been shown in
583numerous studies, including ours, to accurately rank-order
584protein−compound complexes. The MM-GBSA free energy
585consists of five components, namely, the nonpolar and polar
Figure 3. Mode of binding of 3 (IPR-737) upon the central ligand binding cavity of suPARcc. suPARcc is shown as a gray solvent-accessible surface.
3 (IPR-737) is shown as capped sticks. Atoms are color-coded by atom type with N, C, O, Cl, and F colored blue, yellow, red, green, and light blue,
respectively. A 2Fo − Fc electron density map of 3 (IPR-737) at 1σ is colored blue. (b) Crystal structure of 3 (IPR-737) bound to uPAR except that
uPAR is shown as capped sticks to highly hot-spot residues located within the uPAR cavity. Hot spots are shown as red capped sticks. (c) Crystal
structure of the uPAR·3 (IPR-737) complex superimposed on the structure of the uPAR·uPAATF complex to illustrate the overlap between hot spots
on uPA and substituents on 3 (IPR-737).
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586 potential energies, the polar and nonpolar solvation energies,
587 and the entropy (Table S4). The calculated MM-GBSA free
588 energy correlated positively with the experimentally determined
589 Ki values with a Pearson’s r of 0.8, a Spearman’s ρ of 0.41, and a
590 Kendall’s τ of 0.29 (Figure 4a).
591 To gain deeper insight into the interaction of the small
592 molecules with individual residues on uPAR, a decomposition
593 energy calculation was performed for each compound (Figure
594 4b). The decomposition energy consists of polar and nonpolar
595 interaction potential energy, and the polar and nonpolar
596 solvation energies. These calculations were also performed for
597 the uPAR·uPA complex. On uPAR, mutations at 21 residues at
598 the uPAR·uPA interface significantly impaired the interaction.18
599 Among these residues, only a subset is considered hot spots by
600 the traditional definition (ΔΔG > 1 kcal mol−1). Additionally,
601 not all hot spots are included in this list of residues. We
602 examine the local interaction between uPA and compounds
603 with uPAR at these residues (Figure 4c). As expected, uPA
604 strongly engaged these residues. The change in free energy
605 from the experimental alanine scan correlated with the per-
606 residue decomposition (r = 0.38, ρ = 0.17, and τ = 0.01). When
607 only hot-spot residues are considered, the correlation decreases
608 to r = 0.18, ρ = 0.11, and τ = 0.10. At the 21 residues
609 mentioned above, the correlation is r = 0.11, ρ = 0.28, and τ =
610 0.19. Comparison of the decomposition energies of 3 (IPR-
611 737) and 12 (IPR-1175) provides insight into the residues that
612contribute to the ability of 12 to disrupt the protein−protein
613interaction. Compound 3 (IPR-737) decomposition interaction
614energies were much weaker than those observed for uPA. In
615contrast, 12 (IPR-1175) showed much more favorable
616interaction energies that were comparable to those of uPA,
617particularly to Thr-27, Leu-55, Leu-66, and Arg-53. It is
618interesting to note that among all the 21 residues considered,
619the experimental binding affinity of compounds correlated most
620strongly with their interaction energies with Leu-150 and Leu-
621168 with Pearson correlation coefficients of 0.57 and 0.52,
622respectively (Table S5). In addition, the experimental kinetic
623rate constants were also compared to the residue decom-
624position energies of these derivatives (Table S6).
625Arg-53 Enhances Binding through Cooperativity. Arg-
62653 is not considered a hot spot, because alanine scanning
627studies revealed that it contributes only 0.7 kcal mol−1,18 but it
628appears to play a critical role in the binding of small molecules
629as we have demonstrated previously for 2. Considering the
630cation−π interaction of 12 with Arg-53, we hypothesized that
631the residue also plays an essential role in the activity of the
632compound. We explored the possibility that Arg-53 may be
633enhancing interaction of the compound with hot spots through
634cooperative binding. MM-GBSA free energy calculations for
635double mutants that include Arg-53 were also conducted along
636with separate MM-GBSA calculations for the individual
637residues. We ran explicit-solvent molecular dynamics simu-
Figure 4. (a) Plot of the MM-GBSA free energy vs inhibition constant Ki that was measured using the fluorescence polarization assay. The
correlation coefficients of all 12 selected derivatives are as follows: r = 0.48, ρ = 0.41, and τ = 0.29. (b) Decomposition of the free energy of binding
for uPA, 12 (IPR-1175), and 3 (IPR-737). The decomposition energy consists of the interaction energy between the ligand and each residue on
uPAR determined for a collection of snapshots that were obtained from molecular dynamics simulations. (c) Decomposition energies for a select
number of hot-spot and non-hot-spot residues for a set of 1 (IPR-1110) derivatives.
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638 lations and free energy calculations for both the single- and
f5 639 double-mutation states of the uPAR·uPA (Figure 5a) and
640 uPAR·12 (Figure 5b) complexes (Table S7).
641 For the uPAR·uPA complex, mutation of all residues except
642 for one (Leu-66) resulted in a penalty in the MM-GBSA free
643 energy consistent with experimental alanine scanning data for
644 these residues (Figure 5a). The sum of the MM-GBSA free
645 energy change as a result of mutation of Arg-53 and each of the
646 amino acids was nearly always unfavorable as shown in Figure
647 5a. However, it is interesting that when both amino acids (Arg-
648 53 and one of the amino acids in Figure 5) were simultaneously
649 mutated, the resulting change in the MM-GBSA free energy
650 was nearly always different than the sum of the individual
651 mutations (Figure 5a). For example, the sum of the individual
652 mutations of Leu-150 and Arg-53 was 12 kcal mol−1, yet the
653 Leu-150-Ala/Arg-153-Ala double mutation resulted in an only
654 2 kcal mol−1 change in the free energy of binding. Another
655 interesting example is that of Leu-66, for which the sum of
656 individual mutations of this residue and Arg-153 to alanine was
657 4 kcal mol−1, yet the double mutant was much less favorable at
658 nearly 7 kcal mol−1. These results strongly suggest cooperativity
659 between Arg-53 and hot-spot residues toward the binding of
660 uPA to uPAR. For the uPAR·uPA complex, it appears that Arg-
661 53 significantly reduces the size of the contributions of hot
662 spots to the binding of uPA to uPAR.
663 We explored whether Arg-53 and other residues bind to 12
664 in a cooperative manner. In the uPAR·12 complex, mutation of
665 Thr-27, Leu-66, and Leu-168 resulted in more favorable
666binding, while mutation of the other residues resulted in a
667loss of affinity of 12 for uPAR (Figure 5b). Mutation of Arg-53
668to alanine, as expected, resulted in the most pronounced effect
669on the binding of 12 to uPAR. The sum of the contributions of
670Arg-53 and other residues was unfavorable in nearly every case.
671Interestingly, double mutants also consistently exhibited an
672unfavorable effect that was different from the effect of the sum
673of each mutation. For example, in the case of Thr-27, mutation
674of this residue along with Arg-53 resulted in a 5 kcal mol−1
675increase in the free energy of binding compared with only 2
676kcal mol−1 for the sum of the free energy change of individual
677mutations. A similar increase was found for Leu-66 and Leu-
678168. For the other residues, the double mutant showed a
679change in the free energy less pronounced than the sum of the
680free energy change for the individual mutations. For example,
681mutation of Leu-55 and Arg-53 to alanine resulted in a
682combined free energy change of 9 kcal mol−1, while the Leu-55-
683Ala/Arg-53-Ala double mutation resulted in a 7 kcal mol−1 less
684favorable interaction. Other than for Val-125, Arg-53 exhibited
685cooperativity with each of the residues that were considered.
686Interestingly, double mutants with Arg-53 and another residue
687all resulted in unfavorable energy for both uPAR·uPA and
688uPAR·12 complexes. Interestingly, for two of the hot spots,
689Leu-66 and Leu-150, Arg-53 enhances the interaction of 12
690with uPAR by a combined 5 kcal mol−1, while Arg-53 weakens
691the interaction of 12 with hot-spot Leu-55 by 2 kcal mol−1.
692Small-Molecule uPAR·uPA Inhibitors Alter uPAR
693Dynamics. The cooperativity among residues prompted us
694to explore the effect of the two classes of compounds on the
695dynamics of uPAR. We investigated the correlation of the
696motion of 3, 12, and several other compounds to each residue
697 f6on uPAR (Figure 6a). Visual inspection of the color-coded map
698in Figure 6a reveals a dramatic difference in the correlation
699profile of compounds. For example, pyrrolinone 12 and
700derivatives generally shows strong correlated motion with
701residues 1−60 on uPAR, while pyrazole 3 shows no correlation.
702To compare the effect of 3 and 12 on the dynamics of uPAR
703with uPA, we generated a cross-correlated map of the motion of
704uPAR in the presence of uPA (Figure 6b). Interestingly, the
705effects of 12 on the dynamics of uPAR were remarkably similar
706to those of uPA on uPAR (Figure 6c,e), while 3 (Figure 6d)
707showed little correlation. These results suggest small molecules
708that replicate the dynamics of the native ligand in a protein−
709protein interaction are more likely to disrupt the interaction.
710■ DISCUSSION
711Protein−protein interactions range from transient to tight.
712Transient interactions are weaker micromolar-affinity inter-
713actions that typically involve simpler binding epitopes such as a
714linear peptide bound to a cavity.61,62 Tight interactions occur
715between proteins with single- or double-digit nanomolar-range
716binding constants. Tight interactions involve larger interfaces
717(1000−3000 Å2) with binding epitopes consisting of a single
718secondary structure such as an α helix, or a more complex
719binding epitope that spans multiple secondary structures.1,2,63
720While there are numerous examples of small molecules that
721disrupt weak protein−protein interactions, only a few tight
722interactions have been successfully inhibited with small
723molecules.1 Despite the smaller footprint of small molecules
724compared with the large protein−protein interface of tight
725interactions with complex epitopes, it has been suggested that
726small molecules disrupt these interactions by engaging hot
Figure 5. Cooperativity of singly and doubly mutated (a) uPAR·uPA
and (b) uPAR·12 complexes. The difference and standard error
between the free energy of each mutant with the respective wild-type
complex (blue), the sum of the ΔΔG of the Arg-53-Ala mutant and
the single mutant (red), and the double mutant (green). Statistical
significance (independent two-sample t test): *p < 0.01, **p < 0.001,
and ***p < 0.0001.
Biochemistry Article
DOI: 10.1021/acs.biochem.6b01039
Biochemistry XXXX, XXX, XXX−XXX
K
727 spots at the interface.9,26,27 Hot spots can be located on either
728 the ligand or the receptor binding cleft.5,8,64
729 Here, we explore small-molecule antagonists of the uPAR·
730 uPA interaction, a tight and stable protein−protein interaction.
731 The uPAR·uPA interface has a well-defined binding cavity that
732 contains multiple hot-spot residues that contribute ≥1 kcal
733 mol−1 to the binding affinity. These hot spots are located on
734 both uPAR and its ligand, uPA. Small molecules that (i) mimic
735 the position of hot spots on the ligand (uPA) and (ii) engage
736 hot spots on the receptor (uPAR) are expected to disrupt this
737 interaction. Previously, we had identified two classes of
738 compounds that disrupt the protein−protein interaction. The
739 first compound, 2, was identified by docking a commercial
740 library to an ensemble of structures of uPAR collected from
741 molecular dynamics simulations.24 The compound showed
742 binding affinity in the submicromolar range and an IC50 for
743 disruption of uPAR·uPA interaction in the single-digit micro-
744 molar range. Interestingly, the predicted mode of binding of 2
745 to a structure of uPAR sampled from molecular dynamics
746 simulation revealed a salt bridge between the benzoic acid
747 moiety of 2 and Arg-53.24 A recent crystal structure of an
748 analogue of 2 bound to uPAR confirmed our predicted binding
749 mode of the compound and supported the existence of a salt-
750 bridge interaction with Arg-53.20 Arg-53 is buried in the crystal
751structure of the uPAR·uPA complex. The snapshot of 2 bound
752to uPAR that emerged from our molecular dynamics
753simulations revealed an exposed Arg-53. Interestingly, the apo
754structure of uPAR, which was determined after we discovered 2,
755reveals an exposed Arg-53.65 This supported our rationale for
756using molecular dynamics simulations to sample conformations
757that differ from the structure of uPAR in its complex with uPA.
758The second class of uPAR·uPA antagonists that we discovered
759were pyrrolinone compounds.23 Interestingly, these com-
760pounds were identified in a ligand-based approach using the
761structure of pyrazole, pyrrolodinone, piperidinone, and butan-
762amine compounds that were identified by structure-based
763virtual screening using the structure of uPAR from the uPAR·
764uPA complex.21 The carbon that bears the hydroxyl group of
765the pyrrolinone compounds considered in this work may be
766prone to attack by nucleophiles. However, the OH group
767makes a poor leaving group, making covalent adduct formation
768between the compound and protein unlikely. We confirmed
769this with mass spectrometry. Further evidence that argues
770against the formation of a covalent adduct is the fact that
771replacement of OH with a methoxy or isopropoxy, each of
772which is a much better leaving group than OH is, resulted in
773lower-affinity compounds. Also, the lack of exposed nucleo-
774philes such as cysteine residues on uPAR makes it highly
Figure 6. (a) Dynamic cross-correlation matrix (DCCM) cross section of 3 and select derivatives of 1 with uPAR. (b) DCCM of uPAR in the uPAR·
uPA complex, colored using the same scheme used for panel a. (c) Pearson’s correlation between the cross-correlation of uPAR·3 and uPAR·12
complexes and the cross-correlation of individual residues of uPAR in the uPAR·uPA complex. Stereoviews of three-dimensional structures of uPAR
in the (d) uPAR·3 and (e) uPAR·12 complexes, colored on the basis of the correlation coefficient in panel c from positive correlation (blue) to no
correlation (white) to negative correlation (red).
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775 unlikely that 1 and derivatives covalently attach to uPAR. In
776 addition, we show that the compound is stable in buffer,
777 methanol, and uPAR.
778 We synthesize nearly 50 derivatives of pyrollinone 1 to
779 explore the uPAR·uPA protein−protein interaction. We
780 determined the crystal structure of a derivative of 1, namely
781 12 (IPR-1175), and a pyrazole compound 3 (IPR-737) that
782 binds to uPAR but does not disrupt the uPAR·uPA interface.
783 The structures reveal that the pyrazole compounds bind to a
784 site on uPAR that is occupied by a uPA side chain located on
785 the β strands of the β turn of the GFD domain of uPA. The 2-
786 pyrrolinone compound, however, adopts a different binding
787 mode. In addition, the compound comes in direct contact with
788 several hot spots. This explains why both compounds bind to
789 uPAR but only the 2-pyrrolone inhibits uPAR·uPA interaction
790 within the 100 μM concentration range considered in this
791 work. It was interesting that two of the aromatic rings of 12
792 engaged Arg-53, directly forming highly favorable cation−π
793 interactions. Cation−π interactions are electrostatic interactions
794 that are considered to be among the strongest noncovalent
795 interactions in protein structures,66 while mutation of this
796 residue seems to be a common feature of small molecules that
797 we have found to inhibit the uPAR·uPA protein−protein
798 interaction. Previously, we found that a salt-bridge interaction
799 between a benzoic acid moiety on 2 (IPR-803) and the
800 guanidinium ion of Arg-53 was the critical factor that led to
801 inhibition of uPAR·uPA interaction.24 Removal of the benzoic
802 acid led to loss of inhibition of the protein−protein interaction.
803 The use of hot spots on uPAR and uPA in future studies is
804 expected to lead to derivatives that are substantially more
805 potent than the parent compound. This could be achieved by
806 enhancing the affinity of compounds to individual hot-spot
807 residues or by mimicking critical hot spots located on uPA,
808 such as Phe-25 or Trp-30.
809 While Arg-53 is not considered a hot spot, its interaction
810 with small molecules appears to be essential for successful
811 inhibition of the uPAR·uPA interaction by small molecules.
812 Interestingly, molecular dynamics simulation-based free energy
813 decomposition reveals that Arg-53 makes the strongest
814 interaction with uPA compared with other uPA residues that
815 come in contact with uPAR. Despite the strong interaction,
816 alanine scanning studies show that Arg-53 only moderately
817 contributes to the binding affinity (0.7 kcal mol−111). This can
818 be explained by the fact that decomposition energies do not
819 take into consideration the configurational entropy contribu-
820 tions to the binding, in contrast to the alanine scanning that
821 used surface plasmon resonance, which includes both enthalpy
822 and entropy. Considering the position of Arg-53 within the
823 core structure of uPAR, it is possible that mutation of Arg-53
824 may have destabilized uPAR and hence enhanced entropy
825 contributions to the binding affinity, despite the significant loss
826 of enthalpy. Small-molecule inhibitors are expected to disrupt
827 only the interaction of residues and not their contributions to
828 the entropy of binding. This suggests that residues that are not
829 considered hot spots should not be ignored in the design of
830 small-molecule protein−protein interaction inhibitors.
831 The discovery of hot spots at protein−protein interfaces was
832 a significant breakthrough in the field of protein−protein
833 interaction drug discovery. The primary tools to identify hot
834 spots is to systematically mutate each residue to alanine and
835 measure the effect on the binding thermodynamics and kinetics.
836 This process is known as alanine scanning. One limitation of
837 these alanine scanning experiments is that they do not consider
838the effects of neighboring residues, which may enhance or
839weaken the contributions of individual residues.67,68 How to
840take advantage of hot spots for small-molecule drug discovery is
841still unclear. To gain deeper insight into the role of Arg-53 in
842the binding of the small-molecule inhibitors, we explored
843whether any cooperativity between the residue and other
844residues that come in contact with 1 exists. Interestingly, we
845found that the independent mutation of Arg-53 and other hot
846spots resulted in changes in the predicted binding affinity that
847were different from those measured when both Arg-53 and hot
848spots were mutated. For uPA, mutation of hot spots resulted in
849a less favorable MM-GBSA free energy for six of the seven
850mutations, yet mutations of Arg-53 and each of these residues
851resulted in dramatically different free energy changes. For
852example, the mutation of Arg-53 and Leu-150 led to a
853combined 13 kcal mol−1 MM-GBSA free energy change, yet the
854combined mutation of these two residues resulted in a change
855of only 2 kcal mol−1, a dramatic difference. For compound 12,
856mutation of Arg-53 and Leu-150 led to MM-GBSA free energy
857changes of 6 and 2 kcal mol−1, respectively. This is in contrast
858to the dual mutation of both residues that resulted in an
859unfavorable change of >9 kcal mol−1.
860In summary, our work provides insight into the forces that
861drive small molecules to disrupt tight and stable protein−
862protein interactions. We show that mere binding is not a
863sufficient requirement for disrupting the uPAR·uPA protein−
864protein interaction. Even binding to hot-spot residues is not a
865guarantee of disruption of the protein−protein interaction. We
866find that residues that are not considered hot spots in alanine
867scanning experiments such as Arg-53 in uPAR can provide a
868strong anchor for small molecules to enhance their binding
869affinity. These anchors can also strengthen binding of small
870molecules to other hot spots through cooperativity. Also, salt-
871bridge and π−cation interactions appear to be critical for
872disruption of the uPAR·uPA interaction. A previously
873discovered uPAR antagonist, IPR-803, formed a salt-bridge
874interaction that was essential for inhibition of uPAR·uPA
875interaction,24 and compounds reported in this work bind to
876Arg-53 through π−cation interactions. These types of
877interactions are likely to be favorable at protein−protein
878interfaces considering the shallow nature of the pockets and the
879high degree of solvent exposure. These interactions may be a
880straightforward strategy for enhancing the inhibition potency of
881compounds that bind to the target. Another important finding
882of this work is the importance of molecular dynamics in the
883inhibition of tight PPIs by small molecules. We discovered that
884small molecules that inhibit uPAR·uPA interaction alter the
885dynamics of uPAR in a manner similar to that of uPA. This
886suggests that drug discovery efforts targeting protein−protein
887interactions should also consider the effect of compounds on
888the dynamics of the receptor as opposed to merely focusing on
889the interaction energy. Small molecules that bind tightly to hot
890spots and also modulate the dynamics of the receptor in a
891manner similar to that of the native tight ligand are expected to
892lead to more effective inhibitors. These findings can help guide
893the design of derivatives of IPR-1110 through modification of
894the core structure of the compound or by the introduction of
895new substituents.
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